New York State Common Retirement Fund
CSTL icon

New York State Common Retirement Fund’s Castle Biosciences CSTL Stock Holding History

New York State Common Retirement Fund’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.6M Buy
234,746
+1,700
+0.7% +$37.9K 0.01% 1034
2026
Q1 		$5.72M Hold
233,046
– – 0.01% 967
2025
Q4 		$9.07M Buy
233,046
+3,000
+1% +$96.7K 0.01% 773
2025
Q3 		$5.24M Buy
230,046
+14,216
+7% +$289K 0.01% 1047
2025
Q2 		$4.41M Buy
215,830
+52,671
+32% +$975K 0.01% 1107
2025
Q1 		$3.27M Sell
163,159
-25,942
-14% -$642K ﹤0.01% 1221
2024
Q4 		$5.04M Buy
189,101
+5,170
+3% +$157K 0.01% 1100
2024
Q3 		$5.25M Sell
183,931
-3,800
-2% -$96.7K 0.01% 1079
2024
Q2 		$4.09M Sell
187,731
-40,848
-18% -$910K 0.01% 1212
2024
Q1 		$5.06M Sell
228,579
-8,547
-4% -$186K 0.01% 1110
2023
Q4 		$5.12M Sell
237,126
-8,742
-4% -$154K 0.01% 1104
2023
Q3 		$4.15M Buy
245,868
+4,635
+2% +$81.1K 0.01% 1183
2023
Q2 		$3.31M Buy
241,233
+20,308
+9% +$412K ﹤0.01% 1330
2023
Q1 		$5.02M Buy
220,925
+6,447
+3% +$158K 0.01% 1162
2022
Q4 		$5.05M Buy
214,478
+9,244
+5% +$214K 0.01% 1175
2022
Q3 		$5.35M Buy
205,234
+9,435
+5% +$265K 0.01% 1126
2022
Q2 		$4.3M Buy
195,799
+46,935
+32% +$1.09M 0.01% 1267
2022
Q1 		$6.68M Buy
148,864
+20,688
+16% +$855K 0.01% 1152
2021
Q4 		$5.5M Buy
128,176
+80,837
+171% +$4.22M 0.01% 1257
2021
Q3 		$3.15M Buy
47,339
+2,199
+5% +$155K ﹤0.01% 1513
2021
Q2 		$3.31M Buy
45,140
+14,422
+47% +$953K ﹤0.01% 1560
2021
Q1 		$2.1M Buy
30,718
+5,700
+23% +$428K ﹤0.01% 1755
2020
Q4 		$1.68M Sell
25,018
-4,450
-15% -$241K ﹤0.01% 1776
2020
Q3 		$1.52M Buy
29,468
+9,750
+49% +$434K ﹤0.01% 1709
2020
Q2 		$743K Buy
19,718
+14,218
+259% +$486K ﹤0.01% 2024
2020
Q1 		$164K Hold
5,500
– – ﹤0.01% 2550
2019
Q4 		$189K Buy
+5,500
New +$134K ﹤0.01% 2761

Other funds holding CSTL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

New York State Common Retirement Fund's CSTL Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Castle Biosciences (CSTL) stake by 0.73% in Q2 2026, buying an estimated $37.9K and bringing the position to 234,746 shares worth $5.6M. The position accounts for 0.01% of the portfolio, ranked #1034.

New York State Common Retirement Fund first reported a position in CSTL in Q4 2019 and has held it in 27 quarters since. The position peaked at $9.07M in Q4 2025. 38 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • New York State Common Retirement Fund held 234,746 shares of Castle Biosciences worth $5.6M as of Q2 2026.
  • New York State Common Retirement Fund bought 1,700 Castle Biosciences shares in Q2 2026, an estimated $37.9K.
  • Castle Biosciences made up 0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1034 holding.
  • New York State Common Retirement Fund first reported a position in Castle Biosciences in Q4 2019 and has held it in 27 quarters since.
  • New York State Common Retirement Fund's Castle Biosciences position peaked at $9.07M in Q4 2025.
  • 38 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.